Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
The Lancet Oncology ( IF 51.1 ) Pub Date : 2020-02-26 , DOI: 10.1016/s1470-2045(20)30011-5
Shukui Qin ₁ , Zhenggang Ren ₂ , Zhiqiang Meng ₃ , Zhendong Chen ₄ , Xiaoli Chai ₅ , Jianping Xiong ₆ , Yuxian Bai ₇ , Lin Yang ₈ , Hong Zhu ₉ , Weijia Fang ₁₀ , Xiaoyan Lin ₁₁ , Xiaoming Chen ₁₂ , Enxiao Li ₁₃ , Linna Wang ₁₄ , Chunxia Chen ₁₄ , Jianjun Zou ₁₄

Affiliation

Cancer Centre of Jinling Hospital, Nanjing, China.
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Minimally Invasive Therapy Center, Shanghai Cancer Center, Fudan University, Shanghai, China.
Department of Medical Oncology, Second Hospital of Anhui Medical University, Hefei, China.
Department of Intervention, Hunan Cancer Hospital, Changsha, China.
Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Department of Medical Oncology, Third Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China.
Department of Medical Oncology, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
Department of Interventional Radiology, Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, China.
Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), Xi'an, China.
Jiangsu Hengrui Medicine, Shanghai, China.

BACKGROUND Blocking the interaction between PD-1 and its ligands is a promising treatment strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour activity and safety of the anti-PD-1 inhibitor camrelizumab in pretreated patients with advanced hepatocellular carcinoma. METHODS This is a multicentre, open-label, parallel-group, randomised, phase 2 trial done at 13 study sites in China. Eligible patients were aged 18 years and older with a histological or cytological diagnosis of advanced hepatocellular carcinoma, had progressed on or were intolerant to previous systemic treatment, and had an Eastern Cooperative Oncology Group performance score of 0-1. Patients were randomly assigned (1:1) to receive camrelizumab 3 mg/kg intravenously every 2 or 3 weeks, via a centralised interactive web-response system using block randomisation (block size of four). The primary endpoints were objective response (per blinded independent central review) and 6-month overall survival, in all randomly assigned patients who had at least one dose of study treatment. Safety was analysed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT02989922, and follow-up is ongoing, but enrolment is closed. FINDINGS Between Nov 15, 2016, and Nov 16, 2017, 303 patients were screened for eligibility, of whom 220 eligible patients were randomly assigned and among whom 217 received camrelizumab (109 patients were given treatment every 2 weeks and 108 every 3 weeks). Median follow-up was 12·5 months (IQR 5·7-15·5). Objective response was reported in 32 (14·7%; 95% CI 10·3-20·2) of 217 patients. The overall survival probability at 6 months was 74·4% (95% CI 68·0-79·7)]. Grade 3 or 4 treatment-related adverse events occurred in 47 (22%) of 217 patients; the most common were increased aspartate aminotransferase (ten [5%]) and decreased neutrophil count (seven [3%]). Two deaths were judged by the investigators to be potentially treatment-related (one due to liver dysfunction and one due to multiple organ failure). INTERPRETATION Camrelizumab showed antitumour activity in pretreated Chinese patients with advanced hepatocellular carcinoma, with manageable toxicities, and might represent a new treatment option for these patients. FUNDING Jiangsu Hengrui Medicine.

更新日期：2020-02-26

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>